Anzeige
Meldung des Tages: Der neue Superzyklus: Warum Kupfer jetzt strategisch unverzichtbar wird und wer profitieren könnte

ImmunityBio Aktie News

Aktie
WKN:  A2QQ2E ISIN:  US45256X1037 US-Symbol:  IBRX Branche:  Biotechnologie Land:  USA
5,551 €
+0,011 €
+0,20%
07:18:25 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,55 Mrd. €
Streubesitz
18,77%
KGV
-4,88
Index-Zuordnung
-

ImmunityBio News

20.01.26 - WH Selfinvest
Fiserv, Western Digital & ImmunityBio: Lohnen sich diese Aktien jetzt?
20.01.26 - wallstreetONLINE Redaktion
Der nächste Crowd-Trade?: Vom Nischen-Biotech zum Retail-Hype: Diese Aktie dreht brutal auf
Eine Serie starker Studiendaten treibt ImmunityBio in einen Kaufrausch. Der Kurs schießt hoch, das Volumen explodiert – und Leerverkäufer stehen plötzlich im Regen.ImmunityBio ...
16.01.26 - PR Newswire
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
13.09.25 - wallstreetONLINE Redaktion
Meme-Aktien-Alarm: JPMorgan warnt bei diesen vier Meme-Aktien vor Short-Squeeze
JPMorgan warnt: Vier neue Meme-​Aktien locken Kleinanleger und Short-​Seller zugleich. Droht der nächste Short-​Squeeze nach GameStop & Co.? Das sind die Kandidaten.Die Wall ...
28.08.25 - PR Newswire
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone PR Newswire
28.08.25 - PR Newswire
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone PR Newswire
09.07.25 - PR Newswire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Breaking Through: Systemic Genetic Medicines for Hard-​to-Treat Cancers PR Newswire
09.07.25 - PR Newswire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Breaking Through: Systemic Genetic Medicines for Hard-​to-Treat Cancers PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
07.04.25 - PR Newswire
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities PR Newswire

Newssuche

Videos

newspaper
20.01.26 +2,43%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »